18 / 32
CNS target lesions show shrinkage from baseline
•
50 patients (were included in the evaluable for CNS response analysis set)
•
The CNS ORR was 54% (95% CI 39, 68)
•
CNS response was observed regardless of prior RT of the brain
Population: evaluable for response. Scans were performed every 6 weeks
*represents imputed values
CI, confidence interval
100
Best change from baseline in target lesion size (%)
80
60
40
20
0
-20
-40
-60
-80
-100
*
Complete response
Partial response
Stable response
Progressive response
Not evaluable
CNS response to osimertinib in patients with
T790M-positive advanced NSCLC: pooled data
from two phase II trials
Goss Ann Oncol 17